196 related articles for article (PubMed ID: 30508623)
61. Differential response to zinc-induced apoptosis in benign prostate hyperplasia and prostate cancer cells.
Yan M; Hardin K; Ho E
J Nutr Biochem; 2010 Aug; 21(8):687-94. PubMed ID: 19576751
[TBL] [Abstract][Full Text] [Related]
62. Correlation of biochemical (receptors, endogenous tissue hormones) and quantitative morphologic (stereologic) findings in normal and hyperplastic human prostates.
Bartsch G; Keen F; Daxenbichler G; Marth C; Margreiter R; Brüngger A; Sutter T; Rohr HP
J Urol; 1987 Mar; 137(3):559-64. PubMed ID: 2434669
[TBL] [Abstract][Full Text] [Related]
63. TESTOSTERONE AND SERUM ZINC LEVELS IN MEN WITH BENIGN PROSTATIC HYPERPLASIA.
Radhi G; Hilal N; Abdul-Aziz M
Georgian Med News; 2023; (340-341):81-86. PubMed ID: 37805879
[TBL] [Abstract][Full Text] [Related]
64. Light-microscopic stereologic analysis of spontaneous and steroid-induced canine prostatic hyperplasia.
Bartsch G; Bruengger A; de Klerk DP; Coffey DS; Rohr HP
J Urol; 1987 Mar; 137(3):552-8. PubMed ID: 2434668
[TBL] [Abstract][Full Text] [Related]
65. Aromatase inhibition in the dog. II. Effect on growth, function, and pathology of the prostate.
Oesterling JE; Juniewicz PE; Walters JR; Strandberg JD; Steele RE; Ewing LL; Coffey DS
J Urol; 1988 Apr; 139(4):832-9. PubMed ID: 2451040
[TBL] [Abstract][Full Text] [Related]
66. Effects of an extract of Serenoa repens on dogs with hyperplasia of the prostate gland.
Barsanti JA; Finco DR; Mahaffey MM; Fayrer-Hosken RA; Crowell WA; Thompson FN; Shotts EB
Am J Vet Res; 2000 Aug; 61(8):880-5. PubMed ID: 10951976
[TBL] [Abstract][Full Text] [Related]
67. VAT-1 is a novel pathogenic factor of progressive benign prostatic hyperplasia.
Mori F; Tanigawa K; Endo K; Minamiguchi K; Abe M; Yamada S; Miyoshi K
Prostate; 2011 Oct; 71(14):1579-86. PubMed ID: 21394740
[TBL] [Abstract][Full Text] [Related]
68. Effect of baicalein on experimental prostatic hyperplasia in rats and mice.
Guo QL; Ding QL; Wu ZQ
Biol Pharm Bull; 2004 Mar; 27(3):333-7. PubMed ID: 14993798
[TBL] [Abstract][Full Text] [Related]
69. The Impact of
Lee CH; Kwon Y; Park S; Kim T; Kim MS; Kim EJ; Jung JI; Min S; Park KH; Jeong JH; Choi SE
Int J Mol Sci; 2024 Jun; 25(11):. PubMed ID: 38892385
[TBL] [Abstract][Full Text] [Related]
70. Citral and testosterone interactions in inducing benign and atypical prostatic hyperplasia in rats.
Engelstein D; Shmueli J; Bruhis S; Servadio C; Abramovici A
Comp Biochem Physiol C Pharmacol Toxicol Endocrinol; 1996 Oct; 115(2):169-77. PubMed ID: 9568365
[TBL] [Abstract][Full Text] [Related]
71. Induction of atypical prostatic hyperplasia in rats by sympathomimetic stimulation.
Golomb E; Kruglikova A; Dvir D; Parnes N; Abramovici A
Prostate; 1998 Feb; 34(3):214-21. PubMed ID: 9492850
[TBL] [Abstract][Full Text] [Related]
72. In vitro inhibition of 5-α reductase and in vivo suppression of benign prostatic hyperplasia by Physalis angulata ethyl acetate extract.
Nguyen NP; Le QG; Truong VN; Nguyen TND; Phan NTT; Tran MH
Fitoterapia; 2024 Jun; 175():105950. PubMed ID: 38599338
[TBL] [Abstract][Full Text] [Related]
73. Chlormadinone acetate pellet implantation plus short-term oral administration in dogs with benign prostatic hypertrophy.
Kawakami E; Shimizu M; Orima H; Fujita M; Hori T; Tsutsui T
Int J Androl; 1998 Apr; 21(2):67-73. PubMed ID: 9675615
[TBL] [Abstract][Full Text] [Related]
74. Clinical and retrospective evaluation of Eviprostat: a non-hormonal and non-neuropharmacological agent for benign prostatic hyperplasia.
Ishigooka M; Hashimoto T; Hayami S; Tomaru M; Nakada T; Mitobe K
Int Urol Nephrol; 1995; 27(1):61-6. PubMed ID: 7542229
[TBL] [Abstract][Full Text] [Related]
75. Phytoadaptogen correction of clinical and immunobiological parameters in patients with benign prostatic hyperplasia.
Bocharova OA; Matveev VB; Karpova RV; Aksyonov AA; Gorozhanskaya EG; Chebotaryov FN; Katosova LD; Platonova VI; Bochkov NP
Bull Exp Biol Med; 2006 May; 141(5):616-9. PubMed ID: 17181067
[TBL] [Abstract][Full Text] [Related]
76. Induction of benign prostatic hypertrophy in baboons.
Karr JP; Kim U; Resko JA; Schneider S; Chai LS; Murphy GP; Sandberg AA
Urology; 1984 Mar; 23(3):276-89. PubMed ID: 6199881
[TBL] [Abstract][Full Text] [Related]
77. Zonal variation of apoptosis and proliferation in the normal prostate and in benign prostatic hyperplasia.
Colombel M; Vacherot F; Diez SG; Fontaine E; Buttyan R; Chopin D
Br J Urol; 1998 Sep; 82(3):380-5. PubMed ID: 9772874
[TBL] [Abstract][Full Text] [Related]
78. Proliferative responses of cultured rat prostate and human benign prostatic hyperplasia.
Mistry D; Buchanan L; Dattani G; Weaver P; Riches A
Prostate; 1982; 3(3):291-9. PubMed ID: 6179067
[TBL] [Abstract][Full Text] [Related]
79. Three-dimensional conformal radiation therapy of spontaneous benign prostatic hyperplasia in canines.
Zhao P; Lu S; Yang Y; Shao Q; Liang J
Oncol Res; 2011; 19(5):225-35. PubMed ID: 21542458
[TBL] [Abstract][Full Text] [Related]
80. [Phytotherapy of benign prostate syndrome and prostate cancer: better than placebo].
Wehrberger C; Dreikorn K; Schmitz-Dräger BJ; Oelke M; Madersbacher S
Urologe A; 2012 Dec; 51(12):1674-82. PubMed ID: 23160605
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
